Click link below picture

.

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug’s risks.

In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would “take another look” at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis. The medication has been cited as a so-called “suspect” medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.
.
The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago.
.
“What does it take for a drug like this to be taken off the market?” asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.

.

.

.

Click link below for article and videos:

https://www.cnn.com/2018/04/25/health/fda-nuplazid-safety-evaluation-invs/index.html

.

__________________________________________